Armata Pharmaceuticals (ARMP) Free Cash Flow (2013 - 2026)

Armata Pharmaceuticals has disclosed Free Cash Flow across 14 years of filings, most recently posting -$5.8 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$5.8 million, up 23.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$24.5 million (up 32.54% YoY), and the FY2025 annual result was -$26.3 million, up 33.29% from the prior year.
• Free Cash Flow came in at -$5.8 million for Q1 2026 at Armata Pharmaceuticals, up from -$6.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$3.8 million in Q1 2022 to a low of -$19.6 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$9.3 million (2022), against an average of -$9.5 million.
• Across the five-year window, Free Cash Flow sank 421.99% in 2023 and jumped 50.67% in 2025, its largest moves.
• Armata Pharmaceuticals' Free Cash Flow stood at -$10.0 million in 2022, then declined by 4.75% to -$10.5 million in 2023, then rose by 25.28% to -$7.8 million in 2024, then gained by 14.32% to -$6.7 million in 2025, then grew by 13.1% to -$5.8 million in 2026.
• The last three Free Cash Flow figures came in at -$5.8 million (Q1 2026), -$6.7 million (Q4 2025), and -$4.5 million (Q3 2025), per Business Quant data.